EdgarLookup

AstroNova, Inc. — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that AstroNova, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
-1.6%
Profit Margin
Net income ÷ revenue
-1.7%
Return on Assets
Net income ÷ assets
0.79x
Debt-to-Equity
Total liabilities ÷ equity
-0.5%
Revenue Growth
Year over year

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 $150.52M Apr 15, 2026
FY2026 Jan 31, 2025 $151.28M Apr 15, 2026
FY2026 Jan 31, 2024 $148.09M Apr 15, 2026
FY2025 Jan 31, 2023 $142.53M Apr 15, 2025
FY2024 Jan 31, 2022 $117.48M Apr 12, 2024
FY2023 Jan 31, 2021 $116.03M Apr 17, 2023
FY2022 Jan 31, 2020 $133.45M Apr 18, 2022
FY2021 Jan 31, 2019 $136.66M Apr 13, 2021
FY2019 Jan 31, 2018 $113.40M Apr 10, 2020
FY2018 Jan 31, 2017 $98.45M Apr 10, 2019

Revenue (Net Sales)

Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.

Fiscal Year Period End Value Filed
FY2017 Jan 31, 2018 $113.40M Apr 10, 2018
FY2016 Jan 31, 2017 $98.45M Apr 7, 2017
FY2015 Jan 31, 2016 $94.66M Apr 8, 2016
FY2015 Jan 31, 2015 $88.35M Apr 8, 2016
FY2013 Jan 31, 2014 $68.59M Apr 7, 2014
FY2012 Jan 31, 2013 $61.22M Apr 8, 2013
FY2011 Jan 31, 2012 $79.19M Apr 4, 2012
FY2011 Jan 31, 2011 $71.02M Apr 4, 2012

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 $47.63M Apr 15, 2026
FY2026 Jan 31, 2025 $50.66M Apr 15, 2026
FY2026 Jan 31, 2024 $49.51M Apr 15, 2026
FY2025 Jan 31, 2023 $48.16M Apr 15, 2025
FY2024 Jan 31, 2022 $43.74M Apr 12, 2024
FY2023 Jan 31, 2021 $41.36M Apr 17, 2023
FY2022 Jan 31, 2020 $48.76M Apr 18, 2022
FY2021 Jan 31, 2019 $54.00M Apr 13, 2021
FY2019 Jan 31, 2018 $44.00M Apr 10, 2020
FY2018 Jan 31, 2017 $39.49M Apr 10, 2019

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 ($2.38M) Apr 15, 2026
FY2026 Jan 31, 2025 ($14.49M) Apr 15, 2026
FY2026 Jan 31, 2024 $4.69M Apr 15, 2026
FY2025 Jan 31, 2023 $2.66M Apr 15, 2025
FY2024 Jan 31, 2022 $6.43M Apr 12, 2024
FY2023 Jan 31, 2021 $1.28M Apr 17, 2023
FY2022 Jan 31, 2020 $1.76M Apr 18, 2022
FY2021 Jan 31, 2019 $5.73M Apr 13, 2021
FY2019 Jan 31, 2018 $3.29M Apr 10, 2020
FY2018 Jan 31, 2017 $4.23M Apr 10, 2019

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 $1.21M Apr 15, 2026
FY2026 Jan 31, 2025 ($8.64M) Apr 15, 2026
FY2026 Jan 31, 2024 $8.80M Apr 15, 2026
FY2025 Jan 31, 2023 $5.44M Apr 15, 2025
FY2024 Jan 31, 2022 $4.26M Apr 12, 2024
FY2023 Jan 31, 2021 $2.43M Apr 17, 2023
FY2022 Jan 31, 2020 $2.43M Apr 18, 2022
FY2021 Jan 31, 2019 $8.72M Apr 13, 2021
FY2019 Jan 31, 2018 $5.41M Apr 10, 2020
FY2018 Jan 31, 2017 $6.28M Apr 10, 2019

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 $6.79M Apr 15, 2026
FY2026 Jan 31, 2025 $6.05M Apr 15, 2026
FY2026 Jan 31, 2024 $6.34M Apr 15, 2026
FY2025 Jan 31, 2023 $6.82M Apr 15, 2025
FY2024 Jan 31, 2022 $6.75M Apr 12, 2024
FY2023 Jan 31, 2021 $6.21M Apr 17, 2023
FY2022 Jan 31, 2020 $8.08M Apr 18, 2022
FY2021 Jan 31, 2019 $7.81M Apr 13, 2021
FY2019 Jan 31, 2018 $7.45M Apr 10, 2020
FY2018 Jan 31, 2017 $6.31M Apr 10, 2019

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 $11.74M Apr 15, 2026
FY2026 Jan 31, 2025 $4.85M Apr 15, 2026
FY2026 Jan 31, 2024 $12.35M Apr 15, 2026
FY2025 Jan 31, 2023 ($2.94M) Apr 15, 2025
FY2024 Jan 31, 2022 $1.39M Apr 12, 2024
FY2023 Jan 31, 2021 $15.54M Apr 17, 2023
FY2022 Jan 31, 2020 $3.22M Apr 18, 2022
FY2021 Jan 31, 2019 $5.01M Apr 13, 2021
FY2019 Jan 31, 2018 $3.72M Apr 10, 2020
FY2018 Jan 31, 2017 $6.95M Apr 10, 2019

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 $332.0K Apr 15, 2026
FY2026 Jan 31, 2025 $1.17M Apr 15, 2026
FY2026 Jan 31, 2024 $875.0K Apr 15, 2026
FY2025 Jan 31, 2023 $229.0K Apr 15, 2025
FY2024 Jan 31, 2022 $1.80M Apr 12, 2024
FY2023 Jan 31, 2021 $2.59M Apr 17, 2023
FY2022 Jan 31, 2020 $2.91M Apr 18, 2022
FY2021 Jan 31, 2019 $2.65M Apr 13, 2021
FY2019 Jan 31, 2018 $2.20M Apr 10, 2020
FY2018 Jan 31, 2017 $1.24M Apr 10, 2019

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 $137.57M Apr 15, 2026
FY2026 Jan 31, 2025 $145.60M Apr 15, 2026
FY2025 Jan 31, 2024 $133.25M Apr 15, 2025
FY2024 Jan 31, 2023 $139.21M Apr 12, 2024
FY2023 Jan 31, 2022 $114.96M Apr 17, 2023
FY2022 Jan 31, 2021 $115.47M Apr 18, 2022
FY2021 Jan 31, 2020 $116.66M Apr 13, 2021
FY2019 Jan 31, 2019 $118.98M Apr 10, 2020
FY2018 Jan 31, 2018 $122.31M Apr 10, 2019
FY2017 Jan 31, 2017 $83.67M Apr 10, 2018

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 $60.70M Apr 15, 2026
FY2026 Jan 31, 2025 $69.85M Apr 15, 2026
FY2025 Jan 31, 2024 $42.97M Apr 15, 2025
FY2024 Jan 31, 2023 $54.84M Apr 12, 2024
FY2023 Jan 31, 2022 $33.94M Apr 17, 2023
FY2022 Jan 31, 2021 $40.79M Apr 18, 2022
FY2021 Jan 31, 2020 $45.29M Apr 13, 2021
FY2019 Jan 31, 2019 $49.21M Apr 10, 2020
FY2018 Jan 31, 2018 $58.67M Apr 10, 2019
FY2017 Jan 31, 2017 $13.13M Apr 10, 2018

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 $76.86M Apr 15, 2026
FY2026 Jan 31, 2025 $75.75M Apr 15, 2026
FY2026 Jan 31, 2024 $90.28M Apr 15, 2026
FY2026 Jan 31, 2023 $84.37M Apr 15, 2026
FY2025 Jan 31, 2022 $81.01M Apr 15, 2025
FY2024 Jan 31, 2021 $74.68M Apr 12, 2024
FY2023 Jan 31, 2020 $71.38M Apr 17, 2023
FY2022 Jan 31, 2019 $69.78M Apr 18, 2022
FY2021 Jan 31, 2018 $63.65M Apr 13, 2021
FY2019 Jan 31, 2017 $70.54M Apr 10, 2020

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 $17.38M Apr 15, 2026
FY2026 Jan 31, 2025 $16.36M Apr 15, 2026
FY2026 Jan 31, 2024 $14.63M Apr 15, 2026
FY2024 Jan 31, 2023 $14.66M Apr 12, 2024
FY2023 Jan 31, 2022 $12.16M Apr 17, 2023
FY2022 Jan 31, 2021 $12.81M Apr 18, 2022
FY2021 Jan 31, 2020 $12.03M Apr 13, 2021
FY2021 Jan 31, 2019 $12.33M Apr 13, 2021
FY2018 Jan 31, 2018 $13.00M Apr 10, 2019
FY2017 Jan 31, 2017 $4.52M Apr 10, 2018

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 $47.00M Apr 15, 2026
FY2026 Jan 31, 2025 $49.38M Apr 15, 2026
FY2025 Jan 31, 2024 $63.87M Apr 15, 2025
FY2024 Jan 31, 2023 $59.18M Apr 12, 2024
FY2023 Jan 31, 2022 $56.51M Apr 17, 2023
FY2022 Jan 31, 2021 $50.09M Apr 18, 2022
FY2021 Jan 31, 2020 $49.30M Apr 13, 2021
FY2019 Jan 31, 2019 $49.51M Apr 10, 2020
FY2018 Jan 31, 2018 $45.70M Apr 10, 2019
FY2017 Jan 31, 2017 $44.36M Apr 10, 2018

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 $4.07M Apr 15, 2026
FY2026 Jan 31, 2025 $5.05M Apr 15, 2026
FY2025 Jan 31, 2024 $4.53M Apr 15, 2025
FY2024 Jan 31, 2023 $3.95M Apr 12, 2024
FY2023 Jan 31, 2022 $5.28M Apr 17, 2023
FY2022 Jan 31, 2021 $11.44M Apr 18, 2022
FY2021 Jan 31, 2020 $4.25M Apr 13, 2021
FY2019 Jan 31, 2019 $7.53M Apr 10, 2020
FY2018 Jan 31, 2018 $10.18M Apr 10, 2019
FY2017 Jan 31, 2017 $18.10M Apr 10, 2018

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 0 Apr 15, 2026
FY2026 Jan 31, 2025 (1) Apr 15, 2026
FY2026 Jan 31, 2024 0 Apr 15, 2026
FY2025 Jan 31, 2023 0 Apr 15, 2025
FY2024 Jan 31, 2022 0 Apr 12, 2024
FY2023 Jan 31, 2021 0 Apr 17, 2023
FY2022 Jan 31, 2020 0 Apr 18, 2022
FY2021 Jan 31, 2019 0 Apr 13, 2021
FY2019 Jan 31, 2018 0 Apr 10, 2020
FY2018 Jan 31, 2017 0 Apr 10, 2019

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 0 Apr 15, 2026
FY2026 Jan 31, 2025 (1) Apr 15, 2026
FY2026 Jan 31, 2024 0 Apr 15, 2026
FY2025 Jan 31, 2023 0 Apr 15, 2025
FY2024 Jan 31, 2022 0 Apr 12, 2024
FY2023 Jan 31, 2021 0 Apr 17, 2023
FY2022 Jan 31, 2020 0 Apr 18, 2022
FY2021 Jan 31, 2019 0 Apr 13, 2021
FY2019 Jan 31, 2018 0 Apr 10, 2020
FY2018 Jan 31, 2017 0 Apr 10, 2019

Dividends Paid

Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.

Fiscal Year Period End Value Filed
FY2023 Jan 31, 2021 $497.0K Apr 17, 2023
FY2022 Jan 31, 2020 $1.97M Apr 18, 2022
FY2021 Jan 31, 2019 $1.93M Apr 13, 2021
FY2019 Jan 31, 2018 $1.94M Apr 10, 2020
FY2018 Jan 31, 2017 $2.08M Apr 10, 2019
FY2017 Jan 31, 2016 $2.05M Apr 10, 2018
FY2015 Jan 31, 2015 $2.13M Apr 8, 2016
FY2014 Jan 31, 2014 $2.10M Apr 8, 2015
FY2012 Jan 31, 2013 $2.60M Apr 8, 2013
FY2012 Jan 31, 2012 $2.06M Apr 8, 2013